JP2022512781A5 - - Google Patents
Info
- Publication number
- JP2022512781A5 JP2022512781A5 JP2021521816A JP2021521816A JP2022512781A5 JP 2022512781 A5 JP2022512781 A5 JP 2022512781A5 JP 2021521816 A JP2021521816 A JP 2021521816A JP 2021521816 A JP2021521816 A JP 2021521816A JP 2022512781 A5 JP2022512781 A5 JP 2022512781A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- antibody
- hematopoietic stem
- stem cells
- immunosuppressant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024213792A JP2025038016A (ja) | 2018-10-30 | 2024-12-06 | 同種異系の造血幹細胞移植の方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752828P | 2018-10-30 | 2018-10-30 | |
| US62/752,828 | 2018-10-30 | ||
| US201862773873P | 2018-11-30 | 2018-11-30 | |
| US62/773,873 | 2018-11-30 | ||
| US201962882362P | 2019-08-02 | 2019-08-02 | |
| US62/882,362 | 2019-08-02 | ||
| PCT/US2019/058973 WO2020092655A1 (en) | 2018-10-30 | 2019-10-30 | Methods for allogeneic hematopoietic stem cell transplantation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213792A Division JP2025038016A (ja) | 2018-10-30 | 2024-12-06 | 同種異系の造血幹細胞移植の方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022512781A JP2022512781A (ja) | 2022-02-07 |
| JP2022512781A5 true JP2022512781A5 (enExample) | 2022-11-07 |
Family
ID=70462151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521816A Pending JP2022512781A (ja) | 2018-10-30 | 2019-10-30 | 同種造血幹細胞移植の方法 |
| JP2024213792A Pending JP2025038016A (ja) | 2018-10-30 | 2024-12-06 | 同種異系の造血幹細胞移植の方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024213792A Pending JP2025038016A (ja) | 2018-10-30 | 2024-12-06 | 同種異系の造血幹細胞移植の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210379195A1 (enExample) |
| EP (1) | EP3877415A4 (enExample) |
| JP (2) | JP2022512781A (enExample) |
| KR (1) | KR20210086683A (enExample) |
| CN (1) | CN113301923A (enExample) |
| AU (1) | AU2019374055A1 (enExample) |
| BR (1) | BR112021008437A2 (enExample) |
| CA (1) | CA3117366A1 (enExample) |
| IL (1) | IL282637A (enExample) |
| MX (1) | MX2021004579A (enExample) |
| SG (1) | SG11202104084WA (enExample) |
| WO (1) | WO2020092655A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110740641A (zh) | 2016-11-30 | 2020-01-31 | 杰克逊实验室 | 具有改善的人先天免疫细胞发育的人源化小鼠模型 |
| WO2019084057A2 (en) | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| JP2022530443A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗ｃｄ１１７抗体薬物複合体およびその使用 |
| EP3958909A4 (en) * | 2019-04-24 | 2024-01-10 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| GB202015226D0 (en) * | 2020-09-25 | 2020-11-11 | Adc Therapeutics S A | Pyrrol obenzodiazepine-antibody conugates and uses thereof |
| US12496303B2 (en) * | 2020-10-19 | 2025-12-16 | Washington University | Conditioning agents for use in allogeneic hematopoietic stem cell transplantation |
| EP4433512A4 (en) | 2021-11-19 | 2025-12-31 | Univ Pennsylvania | Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy |
| IL313760A (en) * | 2021-12-22 | 2024-08-01 | Jackson Lab | Human mouse models |
| AU2022422572A1 (en) * | 2021-12-23 | 2024-06-06 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd45 for use in cell therapy |
| EP4486784A1 (en) * | 2022-03-01 | 2025-01-08 | CSL Innovation Pty Ltd | Methods of bone marrow conditioning |
| JP2025510189A (ja) * | 2022-03-24 | 2025-04-14 | アクティニウム ファーマシューティカルズ インコーポレイテッド | ヒト化抗ｃｄ４５抗体 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1585799A (en) * | 1997-11-14 | 1999-06-07 | General Hospital Corporation, The | Treatment of hematologic disorders |
| US20120045435A1 (en) * | 2010-08-18 | 2012-02-23 | Theresa Deisher | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| IL263744B2 (en) * | 2016-06-17 | 2023-11-01 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117 plus cells |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| EP3877416A4 (en) * | 2018-10-30 | 2022-07-27 | Magenta Therapeutics, Inc. | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF |
| JP7650819B2 (ja) * | 2019-04-24 | 2025-03-25 | ブイオーアール バイオファーマ インコーポレーテッド | 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用 |
| JP2022535527A (ja) * | 2019-06-04 | 2022-08-09 | マジェンタ セラピューティクス インコーポレイテッド | 自己免疫疾患を治療するための方法および組成物 |
| IL292628A (en) * | 2019-11-01 | 2022-07-01 | Magenta Therapeutics Inc | Anti-cd45 antibody and conjugates accordingly |
-
2019
- 2019-10-30 WO PCT/US2019/058973 patent/WO2020092655A1/en not_active Ceased
- 2019-10-30 CA CA3117366A patent/CA3117366A1/en active Pending
- 2019-10-30 KR KR1020217016249A patent/KR20210086683A/ko active Pending
- 2019-10-30 JP JP2021521816A patent/JP2022512781A/ja active Pending
- 2019-10-30 MX MX2021004579A patent/MX2021004579A/es unknown
- 2019-10-30 EP EP19877673.4A patent/EP3877415A4/en active Pending
- 2019-10-30 SG SG11202104084WA patent/SG11202104084WA/en unknown
- 2019-10-30 AU AU2019374055A patent/AU2019374055A1/en active Pending
- 2019-10-30 CN CN201980085584.8A patent/CN113301923A/zh active Pending
- 2019-10-30 BR BR112021008437-1A patent/BR112021008437A2/pt not_active IP Right Cessation
-
2021
- 2021-04-26 IL IL282637A patent/IL282637A/en unknown
- 2021-04-29 US US17/244,864 patent/US20210379195A1/en active Pending
-
2024
- 2024-12-06 JP JP2024213792A patent/JP2025038016A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512781A5 (enExample) | ||
| JP6741349B2 (ja) | 有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬 | |
| Liu et al. | Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. | |
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| US20260034232A1 (en) | Near Infrared Photoimmunotherapy | |
| JP6427789B2 (ja) | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 | |
| CN109589336B (zh) | 用于t细胞免疫疗法的组合及其用途 | |
| RU2016111137A (ru) | Сконструированные конъюгаты против dll3 и способы применения | |
| AU2010310577A1 (en) | Novel dosing regimen and method of treatment | |
| CN102271711B (zh) | 每种维持移植物抗肿瘤效应的免疫重建促进剂或感染预防剂 | |
| CN118356508A (zh) | 使用抗体-药物缀合物调节免疫应答 | |
| Valent et al. | Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: perspectives and open issues | |
| JP2019511199A (ja) | 新規の抗ｕｐｋ１ｂ抗体及び使用方法 | |
| JP2023514347A5 (enExample) | ||
| Kato et al. | Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia | |
| CN114173820A (zh) | 用于治疗自身免疫疾病的方法和组合物 | |
| Ahmed et al. | The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma | |
| US20060051355A1 (en) | Methods and means for the treatment of immune-related diseases | |
| ES2213355T3 (es) | Cocteles de inmunotoxinas para el tratamiento de enfermedades de origen inmunologico. | |
| Routledge | Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma | |
| BOSTRÖM et al. | Monoclonal antibodies in transplantation: prophylaxis and treatment of | |
| Fishwild | Efficacy of an anti-CD5-ricin A chain immunoconjugate in an improved human peripheral blood lymphocyte--reconstituted severe combined immunodeficient mouse model | |
| NZ736728A (en) | Cd123 antibodies and conjugates thereof | |
| NZ736728B2 (en) | Cd123 antibodies and conjugates thereof | |
| Jurcic | Antibody-Based Therapy of Myeloid Leukemia |